This document provides an investor presentation for Oncolytics Biotech regarding their clinical development program and progress with REOLYSIN, an investigational immuno-oncology viral therapy. Recent progress includes statistically significantly increased overall survival in a phase 2 trial of REOLYSIN in combination with paclitaxel in metastatic breast cancer patients. The clinical development plan focuses on evaluating REOLYSIN in combination with chemotherapy, immunotherapy agents, and targeted therapies to potentially boost multiple aspects of REOLYSIN's mechanism of action. Upcoming milestones include an end-of-phase 2 meeting to discuss the registration pathway in metastatic breast cancer.
11. Path 1: Chemo-Combo / Breast Cancer
• Randomized, non-blinded study, with IV
administered REOLYSIN® given in
combination with paclitaxel versus
paclitaxel alone
• Patients with advanced or metastatic breast
cancer
• Paclitaxel weekly, on days 1, 8 and 15 of a
28-day cycle and test arm with the addition
of REOLYSIN® on days 1, 2, 8, 9, 15 and 16
• 74 patients; powered to 90%
• Endpoints:
• Primary: PFS
• Secondary: OS
• Secondary : ORR
• Secondary: Safety
(IND-213) Phase 2 Data(IND-213) Phase 2 Design
• Statistically significant improvement
in median OS:
• 10.4 months to 17.4 months
• 61 patients presented p53 mutations
• OS more than doubled from 10.4
months to 20.9 months
• First immuno-oncology viral-agent to
demonstrate a statistically significant
median OS advantage in a
randomized clinical study
11
18. Path 3: Targeted/IMiD Combinations
REO + Pomalidomide in multiple myeloma
o Establish safety profile
o Ongoing collaboration with Celgene
& Myeloma UK
o Combined with Revlimid® & Imnovid® as a
rescue treatment in myeloma patients
Enhancement of Innate
Immune Response:
REOLYSIN® + IMiDs
REOLYSIN® alone
REOLYSIN® + IMiDs
Release of
inflammatory
cytokines
Increased
activation of
NK cells
Release of
inflammatory
cytokines
Activation of
NK cells
+ IMiDs
18
22. Patent Portfolio
¡ More than 415 patents issued
worldwide, including 61 US and
20 Canadian
¡ Reovirus issue patent claims cover:
• Compositions of matter comprising reovirus
• Through 2028
• Pharmaceutical use of reoviruses to treat
neoplasia and cellular proliferative diseases
• Combination therapy with radiation,
chemotherapy and/or immune suppressants
• Methods for manufacturing reovirus and
screening for susceptibility to reovirus
• Pharmaceutical use of reoviruses in
transplantation procedures
¡ Over 60 pending
applications worldwide
22
27. Market and Capital Data
Exchanges
OTCQX: ONCYF
TSX: ONC
Market Cap
(May 4, 2017)
USD $72.6 M
CDN $99.9 M
Shares Outstanding
(May 4, 2017)
121,836,722
Options
Restricted/performance share units
(May 4, 2017)
8,032,827
2,222,829
Fully Diluted
(May 4, 2017)
132,092,378
Cash / Cash Equivalents /
Short Term Investments
(March 31, 2017)
CDN $10.1 million
USD $7.3 million*
Cash runway Into 2018
* Based on FX on May 4, 2017
27
28. Investment Highlights
¡ REOLYSIN® statistically significantly increased overall survival
in metastatic breast cancer
¡ More than doubled overall survival in patients with p53 mutation
¡ Strengthened management team: C-Suite and Business Development
¡ Unpartnered immuno-oncology viral agent for systemic
administration exploiting dual activity by cancer cell lysis and anti-
tumor immunity
¡ Defined Clinical Development Program and registration pathway
¡ Extensive patient safety data showing no added significant toxicity
when used as combination with chemotherapy
¡ Manufacturing at commercial scale with sufficient supplies on hand to
support late- stage development and early commercialization
28